Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity, for Parts A and C; if dose-limiting hematologic toxicity is observed on either Part A or C, all subsequent patients enrolled must be evaluable for hematologic toxicity on that Part

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled on Part A must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity for Part A, the dose escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients on Part A1 must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

Patient must not have an antecedent hematologic disorder

Adequate hematologic, hepatic, and renal function

Subject must have adequate hematologic, renal and hepatic function.

Adequate hematologic function

Participants must have adequate hematologic, renal and hepatic function.

Acceptable hematologic status:

Acceptable hematologic status:

Adequate hematologic function

Adequate hepatic, renal, cardiac, and hematologic function

Poor hematologic, renal, or hepatic function

Absolute neutrophil count (ANC) >= 750/uL for subjects with bone marrow involvement; these subjects will not be evaluable for hematologic toxicity or hematologic dose limiting toxicity (DLT), but will be subject to dose modifications based on hematologic criteria

Platelet count >= 75,000/uL (platelet transfusions allowed provided the patient is not known to be refractory to red cell or platelet transfusions) for subjects with bone marrow involvement; these subjects will not be evaluable for hematologic toxicity or hematologic DLT, but will be subject to dose modifications based on hematologic criteria

Acceptable hematologic status

Adequate hematologic, renal, and hepatic parameters

Hematologic function: Adequate bone marrow function is defined as:

Acceptable liver, renal, hematologic and coagulation function

Adequate hematologic, renal, and hepatic function

Adequate hematologic, hepatic, and renal function.

adequate hematologic, renal and hepatic function

Inadequate hematologic function as evidenced by any of the following:

Adequate hematologic function within 28 days prior to study registration defined as meeting all of the following criteria:

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts specified above (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity.

Adequate hematologic, renal, and liver function

Participants with hematologic malignancies

Acceptable hematologic status at Screening

The patient has adequate baseline hematologic function, as demonstrated by the following:

Poor hematologic, renal, or hepatic function

Acceptable hematologic, renal and liver function as follows:

Adequate hematologic parameters unless clearly due to the disease under study

Adequate hematologic status

Hematologic malignancies other than lymphomas.

Inadequate hematologic, renal or hepatic function.

Adequate hepatic, renal, cardiac, and hematologic function.

Hematologic malignancies other than lymphomas.

Have adequate hematologic function within 15 days prior to study treatment, defined as meeting all of the following criteria:

Appropriate renal, liver, and hematologic lab values

Adequate hematologic, renal and hepatic laboratory parameters

Current hematologic malignancies.

Must have adequate hematologic, renal and hepatic function.

Concurrent hematologic or non-hematologic malignancy requiring treatment

Adequate hematologic function

Germ cell or hematologic malignancies

Adequate organ function as per Hematologic, Hepatic, Renal and Cardiac Laboratory Values

Hematologic malignancy

Adequate hematologic, hepatic, and renal function

Adequate hematologic parameters without ongoing transfusional support:

Subjects must have adequate hematologic, hepatic and renal function.

Adequate baseline hematologic, renal, and hepatic function

Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function as defined by criteria below:

Hematologic (BM Function):

Hematologic (Coagulation Factors):

Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis)

Adequate hematologic parameters without ongoing transfusional support:

Patients with solid tumors metastatic to bone marrow will be eligible for study but not evaluable for hematologic toxicity; these patients must not be known to be refractory to red cell or platelet transfusions; at least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity; if dose limiting hematologic toxicity is observed at any dose level, all subsequent patients enrolled must be evaluable for hematologic toxicity

Subjects with known bone marrow metastatic disease will be eligible for study provided they meet the specified blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these subjects will not be evaluable for hematologic toxicity; if dose-limiting hematologic toxicity is observed, all subsequent subjects enrolled must be evaluable for hematologic toxicity

Remission of any acute hematologic malignancy or adequate disease control for chronic malignancies

Adequate hematologic function (unless abnormalities are related to NHL), defined as follows:

Adequate hematologic, hepatic, and renal function

Acceptable hematologic status

Adequate baseline hematologic, renal, and hepatic function

Hematologic malignancies other than lymphomas.

Subject has adequate hematologic function and adequate hepatic function at screening

Patients must have adequate renal/hematologic function, as defined by creatinine clearance > 30ml/min and platelets>50,000.

Adequate hematologic, coagulation (INR 2-3 max), hepatic and renal function

Inadequate hematologic, coagulation (INR >3), hepatic, renal function

Adequate hematologic, renal and hepatic function

Good health with adequate hematologic, renal, hepatic, and cardiac function, as determined by the Investigator, based upon medical history, physical examination, and laboratory test results at the screening visit (Visit 1):

Participant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.

Adequate hematologic parameters without ongoing transfusional support:

Adequate bone marrow function defined as:\t\r\n* Subjects with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these subjects will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent subjects enrolled must be evaluable for hematologic toxicity

Subjects must have adequate renal, hepatic and bone marrow function based on screening laboratory assessments. Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:

Adequate hepatic, renal, cardiac, and hematologic function

Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria; patients with marrow disease are not evaluable for hematologic toxicity

Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma or secondary amyloidosis)

All patients enrolled on the study must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity, for the dose-escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

All patients enrolled on Part A of the study must be evaluable for hematologic toxicity

Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity

Adequate hematologic, renal, and hepatic function.

Untreated first hematologic relapse is defined as:

Adequate hematologic, hepatic, renal, and coagulation function.

Has adequate hematologic (bone marrow and coagulation factors), renal and hepatic function as defined by criteria below:

Hematologic (BM Function):

Hematologic (Coagulation Factors):

Adequate kidney and hematologic function assessed from baseline laboratory data

Participant must have adequate hematologic, renal, hepatic, and lung function.

Part 1: solid tumors or lymphomas, or hematologic malignancies

Adequate hematologic, renal, and hepatic function (within 28 days of randomization).

Adequate hematologic, renal, and hepatic function

Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.

Adequate hematologic, renal, and hepatic function

Have adequate hematologic function.

Adequate hematologic function:

Adequate hematologic function

Acceptable hematologic status:

Diagnosis of any of the following hematologic malignancies:

Adequate hematologic, hepatic, and renal function

Inadequate hematologic, hepatic, or renal function

Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and must have a serum lactate dehydrogenase (LDH) ? 1.0 X upper limit of normal and adequate hematologic, hepatic, renal, and coagulation organ function- Other criteria may apply

Adequate hematologic function

Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function

Adequate hematologic function

Adequate hematologic, renal, and hepatic function determined by laboratory blood and urine tests.

Has adequate hematologic (bone marrow and coagulation factors), renal, and hepatic function as defined by criteria below:

Inadequate hematologic function (unless due to underlying lymphoma)

Adequate hematologic, hepatic, and renal function

Adequate hematologic, liver, coagulation and kidney function

Hematologic and Non-hematologic exclusion criteria before start of therapy.

Adequate renal, hepatic, and hematologic functions per protocol-defined laboratory parameters within ? 7 days before treatment initiation.

Inadequate hematologic, renal, and liver function (unless due to underlying lymphoma)

Adequate hematologic function without growth factor or transfusion support

Adequate hematologic function:

Adequate hematologic, renal and hepatic function, specifically:

Adequate renal, and hematologic function

Adequate hematologic function

Acceptable hematological status (without hematologic support

Adequate renal, hepatic, and hematologic indices for ipilimumab therapy

Inadequate hematologic, renal, or hepatic function

Adequate hematologic, hepatic, renal, and coagulation functions

Adequate hematologic, hepatic, and renal function

Subject has adequate hematologic, hepatic, renal, and coagulation function

Adequate organ function as per pre-defined hematologic, hepatic, renal, and cardiac criteria.

Adequate baseline hematologic function, as demonstrated by the following:

Adequate hepatic, renal, cardiac, and hematologic function

Adequate hematologic status

Adequate hepatic, hematologic, and renal function

Inadequate hematologic or hepatic function

Adequate hematologic, organ, and coagulation within 2 weeks (14 days) prior to randomization.

Adequate hematologic function:

Adequate hematologic, hepatic, and renal function, defined by:

Adequate hematologic function within 28 days prior to registration for protocol therapy defined as meeting all of the following criteria:

Adequate hematologic, hepatic, and renal function

Grossly normal pulmonary, cardiac function, renal, hepatic hematologic and performance functions

Adequate hematologic function as defined by:

Inadequate hematologic, renal or liver function

Adequate hematologic, renal and hepatic function.

Has adequate hematologic, hepatic, and renal function as defined by the protocol

Adequate hematologic, hepatic, and renal function (absolute neutrophil count ?1.5x 109/L, Hgb >10 g/dL, platelet count ?100 x 109/L, AST/ALT ?2.5x ULN, creatinine ?1.5x ULN).

Patients with lymphoma metastatic to bone marrow who have granulocytopenia, anemia, and/or thrombocytopenia will be eligible for study but not evaluable for hematologic toxicity (in Part A, there will be a maximum of one per cohort); such patients must meet the blood counts as in Part A (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled in Part A must be evaluable for hematologic toxicity

Inadequate hematologic, renal or liver function

Adequate hematologic, renal and liver function

Adequate hematologic, hepatic, renal and cardiac function.

Adequate hematologic, hepatic and renal function

Adequate renal, hepatic, and hematologic indices for ipilimumab therapy

No significant hematologic abnormalities

Have adequate hematologic, hepatic, and renal function

Adequate hematologic function

Have adequate hematologic, hepatic and renal function

Adequate hematologic, hepatic and renal function.

Adequate hematologic, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:

Have adequate hematologic function, defined as meeting all of the following criteria:

Adequate hematologic function within protocol-defined parameters.

Adequate hematologic function Arm A (except for CLL subjects with significant BM involvement by biopsy) must meet the following criteria:

Acceptable hematologic and organ function

Adequate hematologic, hepatic, and renal function

Has adequate hematologic, renal, cardiac and hepatic function.

Must have adequate hematologic, renal, and liver function

Adequate hematologic, hepatic, and renal function.

Subject has the following laboratory parameters at screening: Adequate hematologic function including:

Adequate hematologic, hepatic, cardiac, and renal function

Adequate hematologic, hepatic, and renal function.

Not adequate hematologic, renal and hepatic function

Adequate hematologic, renal, and hepatic function.

Patient with significant cardiac, renal or hematologic or pulmonary dysfunction

Adequate hematologic, hepatic, renal function

Adequate hematologic function, as defined by the following criteria:

Subject must have adequate hematologic reserve

Poor hematologic, renal, or hepatic function

Adequate hematologic function.

Adequate hematologic, hepatic, and renal function:

Patient has any of the following hematologic parameters:

Adequate baseline hematologic, pulmonary, renal, and hepatic function

Adequate hematologic, kidney and liver function

Inadequate hematologic or biologic function as determined by the following laboratory tests:

Adequate hematologic, hepatic and renal function

Acceptable hematological status (without hematologic support

Patients must have normal organ and hematologic function therapy

Adequate hematologic function:

Adequate hematologic, renal and hepatic function

Adequate hematologic function defined by:

Adequate hematologic function

Adequate hematologic, liver, coagulation, renal, and cardiovascular function

Evidence of significant hepatic, hematologic, or immunologic disease.

Adequate hematologic, renal and hepatic function

Patients with any of the following hematologic abnormalities at baseline:

Inadequate hematologic, biochemical, and organ function

Subject must have adequate hematologic, renal and hepatic function as follows:

Antecedent hematologic disease

Adequate hematologic, hepatic and renal function

Inadequate hematologic, hepatic or renal function

Patients with any of the following hematologic abnormalities at baseline:

Hematologic:

Hematologic function, as follows:

Hematologic status:

Adequate hepatic, renal, cardiac and hematologic function

Adequate hematologic, hepatic and renal function as defined by laboratory assessment

Adequate hematologic, renal and liver function

Inadequate hematologic, liver, or renal function

Adequate hematologic, liver, and renal function

Hematologic, liver, and renal function as specified in the study protocol.

Has adequate hematologic, liver, and renal function

Adequate hematologic, renal, and liver functions

Adequate hematologic and renal function as determined by laboratory blood and urine tests

Has adequate hematologic, coagulation, hepatic and renal function

Hematologic parameters defined by:

Adequate hematologic function.

Inadequate hematologic function as evidenced by any of the following:

Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician

Participants with adequate hematologic, hepatic, and renal function.

Participant must have adequate hematologic, renal, and hepatic function.

Hematologic malignancy

Adequate hematologic function as indicated by:

Patient has adequate hematologic, hepatic, and renal function as defined by:

Any of the following hematologic malignancies:

Any of the following hematologic malignancies:

Patients must not have evidence of significant hematologic, renal, or hepatic dysfunction

Adequate hepatic, renal, cardiac, and hematologic function

Adequate hematologic, hepatic, and renal function, as evidenced by:

Adequate hematologic, hepatic, and renal function

Adequate hematologic, hepatic, and renal function.

Patient has adequate hematologic, hepatic, and renal functions

Adequate hematologic, immunologic, liver and renal function, defined as